Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Mar 15, 2025; 17(3): 98746
Published online Mar 15, 2025. doi: 10.4251/wjgo.v17.i3.98746
Published online Mar 15, 2025. doi: 10.4251/wjgo.v17.i3.98746
Significance of monitoring imatinib plasma concentration in second-line treatment decisions for c-kit 11 gene-mutated gastrointestinal stromal tumors
Hai-Tao Li, Department of Gastrointestinal Surgery, Nanchuan Hospital of Chongqing Medical University, Chongqing 408400, China
Yun-Yun Du, Department of Oncology, Nanchuan Hospital of Chongqing Medical University, Chongqing 408400, China
Zhen Huang, Jin-Jin Li, Jun Zhang, Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
Co-corresponding authors: Jin-Jin Li and Jun Zhang.
Author contributions: Li HT, Du YY, Huang Z, and Li JJ participated in the acquisition, analysis, and interpretation of the data, and drafted the initial manuscript; Li HT, Li JJ, and Zhang J revised the article critically for important intellectual content; Li JJ and Zhang J designed the study. Li JJ and Zhang J are co-corresponding authors and have contributed equally to this work.
Institutional review board statement: The study was reviewed and approved by the Institutional Review Board of the Nanchuan Hospital of Chongqing Medical University (Approval No. QT-2024-003-01).
Informed consent statement: The need for patient consent was waived due to the retrospective nature of the study.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
Data sharing statement: No additional data are available.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jun Zhang, Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, No. 1 Youyi Road, Yuzhong District, Chongqing 400016, China. zjun2323@sina.cn
Received: July 5, 2024
Revised: November 2, 2024
Accepted: December 16, 2024
Published online: March 15, 2025
Processing time: 224 Days and 3.1 Hours
Revised: November 2, 2024
Accepted: December 16, 2024
Published online: March 15, 2025
Processing time: 224 Days and 3.1 Hours
Core Tip
Core Tip: This study showed that increasing the dosage of imatinib (IM) for patients with advanced gastrointestinal stromal tumors harboring c-kit exon 11 mutation who experienced failure of first-line IM treatment can prolong overall survival when the plasma concentration is < 1100 ng/mL. Switching to another tyrosine kinase inhibitor can improve the disease control rate and achieve longer progression-free survival when the plasma concentration is ≥ 1100 ng/mL. Therefore, IM plasma concentration may guide the decision-making for second-line treatment.